Anti-HIV-1 activities in extracts from some medicinal plants as assessed in an in vitro biochemical HIV-1 reverse transcriptase assay

Phytotherapy Research

Volumn 19, Issue 4, 2005, Pages 287-290

  Kanyara, J N ^a   Njagi, E N M ^b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b KENYATTA UNIVERSITY   (Kenya)

Author keywords

Anti HIV activity; Extracts; HIV 1; IC50; Medicinal plants; Reverse transcriptase assay

Indexed keywords

ACACIA MELLIFERA EXTRACT; ACICLOVIR; ALBIZIA CORIRIA EXTRACT; ALBIZIA GUMMIFERA EXTRACT; AMOXICILLIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; ERYTHROMYCIN; FOSCARNET; MAYTENUS BUCHANANI EXTRACT; MAYTENUS SENEGALENSIS EXTRACT; MELIA AZEDARACH EXTRACT; NEOMYCIN; PLANT EXTRACT; POLYADENYLIC ACID; PYGEUM AFRICANUM EXTRACT; RHUS NATALENSIS EXTRACT; RNA DIRECTED DNA POLYMERASE; TETRACYCLINE; THYMIDINE PHOSPHATE; THYMIDINE TRIPHOSPHATE; UNCLASSIFIED DRUG; VERNONIA JUGALIS EXTRACT;

ACACIA MELLIFERA; ALBIZIA CORIRIA; ALBIZIA GUMMIFERA; ANTIVIRAL ACTIVITY; ARTICLE; DRUG DETERMINATION; DRUG SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MAYTENUS BUCHANANI; MAYTENUS SENEGALENSIS; MEDICINAL PLANT; MELIA AZEDARACH; MICROTITER PLATE ASSAY; NONHUMAN; PYGEUM; RHUS NATALENSIS; STANDARD; VERNONIA JUGALIS;

ANTI-HIV AGENTS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INHIBITORY CONCENTRATION 50; KENYA; MEDICINE, TRADITIONAL; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 23244432885     PISSN: 0951418X     EISSN: None     Source Type: Journal    
DOI: 10.1002/ptr.1536     Document Type: Article

References (20)

1. Abrecht MA, Wilkin JJ, Coakely EPG, Hammer SM. 2003. Advances in antiretroviral therapy. Topics in HIV medicine 11: 97-127.
2. Antoun MD, Rios YR, Medonza NT, Proctor G. 1994. Reverse transcriptase inhibition as pre-screen for potential antiviral bioactives. Puerto Rico Health Sci J 13: 17-18.
3. Barre'-Sinoussi F, Chermann JC, Ray F, et al. 1983. Isolation of T-lymphotropic retrovirus from a patient at risk of acquired immune deficiency syndrome (AIDS). Science 220: 868-870.
4. Clark AM. 1996. Natural products as a resource for new drugs. Pharmaceutical Res 13: 1133-1144.
5. D'Aquila RT. 1994. HIV-1 drug resistance. Molecular pathogenesis and laboratory Monitoring. Clinics Laborat Med 14: 393-422.
6. De Clercq E. 1996. What can be expected from nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the management of human immunodeficiency virus type 1 (HIV-1) infections? Medical Virology 6: 97-117.
7. Debouck C. 1992. The HIV-1 protease as a target for AIDS. AIDS Res Human Retrovir 8: 153-164.
8. Hammer SM, Kessler HA, Saag MS. 1994. Issues in combination antiretroviral therapy: A review. JAIDS 7(suppl 2): S24-S37.
9. Harrigan PR, Stone C, Griffin P, et al. 2000. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J Infectious Dis 181: 912-920.
10. Henry K, Bellman PC, Norris D et al. 2001. Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodefiency virus type 1: results of the TARGET Study. J Infectious Dis 183: 571-578.
11. Hirsch, MS. 1990. Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. J Infectious Dis 161: 845-857.
12. Houghton PJ. 1996. Compounds with anti-HIV activity from plants. Transactions Royal Soc Trop Med Hygiene 90: 601-604.
13. Khanna N, Klimkait T, Schiffer V, et al. 2000. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase and a protease inhibitor in heavily infected patients. AIDS 14: 791-799.
14. Kokwaro JO. 1993. Medicinal Plants of East Africa, 2nd edn. Kenya Literature Bureau Nairobi, Kenya.
15. Kurokawa M, Ochiai H, Nagasaka K, et al. 1993. Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1, infection. Antiviral Res 22: 175-188.
16. Neuzil KM. 1994. Pharmacologic therapy for human immunodeficiency virus infection: A review. Am J Medic Sci 7: 368-373.
17. Pitha PM. 1994. Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res 24: 205-219.
18. Tan GT, Pezzutto JM, Kinghorn AD, Hughes SH. 1991. Evaluation of natural products as inhibitors of human immunodefficiency virus type 1 (HIV-1) reverse transcriptase. J Natural Products 54: 143-154.
19. Yarchoan R, Mitsuya H, Weinhold KJ, et al. 1985. 3′-azido-3′- deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy- associated virus in vitro. Proceed National Acad Sci USA 82: 7096-7100.
20. Yuen GJ, Lou Y, Thompson NF, et al. 2001. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food absorption. J Clin Pharmacol 41: 277-288.